

Appendix 1 (2024/25):

Banding criteria and service payments for 'Monitoring of Drugs in Primary Care'

Banding	Payment per drug patient per year	Typical monitoring requirements
Band 1	£91.95	high intensity monitoring
Band 2	£45.97	intermediate
Band 2b	£26.56	inclisiran and oral anti-psychotics
Band 3	£7.15	closer to routine and/or infrequent

The following general definitions are used to assist determination of which banding specific drugs will fall into. The detail below is NOT the definition of monitoring requirements for each drug within that banding. For monitoring requirements for each drug, please refer to the current monitoring or shared care guidelines for the drug (or group of drugs) from the relative hospital provider.

Band 1: £91.95 per drug per patient per year

Monitoring every one-two months of U&Es, LFTs, FBCs.

Include ECG, respiratory function tests etc. more than once a year.

Verbal interview and record keeping of symptom checklist.

Reporting of concerns to specialist.

Band 2: £45.97 per drug per patient per year

Monitoring more than twice a year up to and including every three months.

Include ECG, respiratory function tests etc. once a year.

Verbal interview and record keeping of symptom checklist.

Reporting of concerns to specialist.

Band 2b: £26.56 per drug per patient per year

Excluding the use of these drugs for end of life care

Monitoring typically twice a year but may be up to and including every three months.

Include ECG, respiratory function tests etc. once or twice a year in relevant patients.

Verbal interview and record keeping of symptom checklist.

Reporting of concerns to specialist.

Band 3: £7.15 per drug per patient per year

Monitoring twice a year or less often

Two or more of the following: U&Es, LFTs, FBCs

Verbal interview and record keeping of symptom checklist.

Reporting of concerns to specialist.

Appendix 2 (2024/25):

Banding decisions on drugs included in the 'Monitoring of Drugs in Primary Care' service

Current versions of monitoring or shared care protocols should be accessed via the website of the relevant NHS commissioned provider, e.g.:

- York and Scarborough Formulary: www.yorkandscarboroughformulary.nhs.uk/
- Harrogate Formulary: <http://www.harrogateformulary.nhs.uk/>
- North East and North Cumbria Formulary: [North East and North Cumbria Formulary \(northeastnorthcumbriaformulary.nhs.uk\)](http://www.northeastnorthcumbriaformulary.nhs.uk/)
- Tees, Esk & Wear Valleys NHSFT at: [see NENC formulary above](#)
- Leeds Formulary: <http://www.leedsformulary.nhs.uk/default.asp>
- The Retreat, York: [Protocols adopted from TEWV still to be approved and added to website](#)

Band 1:

Frequent blood testing, in respect of the following specified drugs:

Aripiprazole (depot injection)	Azathioprine (po)
Ciclosporin (po)	Degarelix (inj.)
Flupentixol (inj.)	Fluphenazine (inj.)
Haloperidol decanoate (inj)	Leflunomide (po)
Mercaptopurine (po)	Methotrexate (po and s/c)
Mycophenolate (po)	Paliperidone (depot injection)
Penicillamine (po)	Risperidone (inj.)
Sulphasalazine (po)	Tolcapone (po)
Zuclopenthixol (decanoate inj only)	

Band 2:

Monitoring, including blood testing, or other special monitoring or other special circumstances, in respect of the following drugs:

Atomoxetine (po)	Dapsone (po)
Denosumab (inj)	Dexamfetamine (po)
Dronedarone (po)	Goserelin (imp)
Guanfacine (po)	Hydroxycarbamide (po) (psoriasis only)
Leuprorelin (inj)	Lisdexamphetamine (po)
Methylphenidate (po)	Metyrapone (po)
Riluzole (po)	Sirolimus (po)
Tacrolimus (po)	Triptorelin (inj)

Entecavir **only** when prescribed under a shared care agreement with tertiary centre

Lamivudine **only** when prescribed under a shared care agreement with tertiary centre

Tenofovir disoproxil fumarate **only** when prescribed under a shared care agreement with tertiary centre

Band 2b:

Inclisiran and oral anti-psychotics (excluding when used for end of life care), in respect of the following drugs (regular anti-psychotic injections are in band 1):

Amisulpiride (po)	Aripiprazole (po)
Benperidol (po)	Chlorpromazine (po)
Flupentixol (po)	Haloperidol (po)
Inclisiran (inj) (NB: included in band 2b for administration for lipid management)	
Lithium (po)	Lurasidone (po)
Olanzapine (po)	Paliperidone (po)
Pericyazine (po)	Pimozide (po)
Promazine (po)	Quetiapine (po)
Risperidone (po)	Sulpiride (po)
Trifluoperazine (po)	Zuclopenthixol (po)

Band 3:

Routine monitoring of the following drugs:

Amiodarone (po)	Apomorphine (inj)
Bromocriptine (po)	Cabergoline (po)
Darbepoetin alfa (inj)	Donepezil (po)
Epoetin (inj)	Galantamine (po)
Hydroxychlorquine sulphate (po)	Lanreotide (inj)
Memantine (po)	Mexiletine (po)
Modafinil (po)	Octreotide (inj)
Pergolide (po)	Rivastigmine (po)
Sodium valproate , valproic acid, valproate semisodium (po) (for women of child bearing potential)	
Testosterone (all formulations for male hypogonadism)	
Ulipristal acetate 5mg (po)	

Confirmed additions which are new for 2024/25 are underlined.

Confirmed banding changes for 2024/25 are marked with an *

Confirmed removals for 2024/25 are scored through and marked REMOVED